We have previously reported that a 'universal' growth law with fixed scaling exponent p, as proposed by West and collaborators for all living organisms, appears to be able to describe also the growth of tumors in vivo. Here, we investigate in more detail the dynamic behaviour of p using data from the literature. We show that p initially decreases before it again increases up to or even beyond 3/4. These results support the notion that p can vary over time and yet its dynamics are independent from the cancer type. We argue that this behaviour reflects the underlying evolving tumorigenesis in that the minimum of p signals the emergence of a fractal-like distribution network corresponding to the 'angiogenetic switch' towards a perfusion-dominated nutrient supply mechanism.
Introduction
In a previous paper we reported that West et al. 's model of 'universal growth' (West et al, 2001) can also describe the growth dynamics of experimental in vivo tumors and, furthermore, that it can also be applied to selected data from experimental tumors as well as clinical cancer data (Guiot et al, 2003) . In that study, the scaling exponent p is assumed to be fixed over time. Here, we introduce a modification to our tumor growth model allowing the exponent p to vary dynamically and continuously over time to reflect changes in the nutrient-supply mechanisms during tumorigenesis.
Using our dynamic framework, we investigate biomedical data reported in the literature to test the validity of the proposed mechanisms.
According to West et al (2001) , the actual mass m and its rate of growth, dm/dt, are nonlinearly related:
where M is the asymptotic value of m(t) and a is a parameter related to the metabolic rate of the particular tumor cell line. It can be shown using Eq. (1) 
West et al argue that the main mechanism for nutrient supply is related to the fractal-like distribution network, and propose the exponent p = 3/4 as a universal scaling factor. For tumors, this assumption implies the presence of an angiogenetic network, hence primarily corresponds to active perfusion for tumor growth in vivo. Determining the proper value of the scaling exponent p, however, remains a controversial issue. For example, a recent paper (Dodds et al, 2001) shows that p = 3/4 does not yield a significantly better fit of all available data than p = 2/3 (which derives from a simple dimensional analysis).
Materials and Methods
To investigate the behaviour of the power exponent p in experimental in vivo tumors, we examine data reported in Steel (1977) . In order to estimate the optimal value of p, instead of assuming it fixed 'ab initio', we solve Eq. (2) for p using the aforementioned data to estimate values of µ and dµ/dt from the growth curves and then iteratively compute the value of p for which the difference between the predicted and observed values is smallest. In principle the value of b, which is a biological parameter and is expected to depend on the cell line, should be independently measured.
Since direct measures are not available at the moment, we first assume a tentative constant value for b, and then perform a recursive, autoconsistent procedure to estimate p at any time. Then the value of b is changed and the procedure repeated until a satisfactory "best fit" is reached for both p and b.
Results
Using the procedure outlined above, we obtain the p(t) plots presented in Fig. 1 . In this study here,
we investigate three out of five cell lines of tumors growing in mice as reported in Steel (1977) 1 .
Note that, regardless of the cancer type, the scaling exponent p now changes dynamically, i.e., it initially decreases to a minimum before it eventually rises again. From our formalism or, directly from is complemented by another supply mechanisms, likely by passive diffusion, when vascular density approaches its plateau phase. We further argue that such an increased surface diffusion can be explained by the onset of central apoptosis and necrosis, which should reduce the actively metabolizing tumor (cell) volume (V a ) while restricting it to the highly proliferating tumor surface, and hence effectively raises the [S/V a ] ratio. In addition, we found, that for the data analyzed here, this dynamic p-behaviour appears to be independent of cancer type. It is also noteworthy that the absolute time τ at which p reaches its minimum turns out to be very similar across the different tumor cell lines. Together, these findings further support our conjecture about the universality of the tumor growth model. 
